文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

甲氧苄啶-磺胺甲噁唑相关严重急性呼吸衰竭的定义与临床评估

Definition and Clinical Evaluation for Trimethoprim-Sulfamethoxazole Severe Acute Respiratory Failure.
PubMed 文献 · Crit Care Med · 2023-07-14
一句话结论接受治疗剂量甲氧苄啶-磺胺甲噁唑≥6天者出现不明原因严重呼吸衰竭,应警惕该罕见药物不良反应,死亡率接近40%。

该回顾性研究纳入1996至2021年美国ICU收治的19例10-37岁既往健康、无肺部疾病及其他呼吸衰竭病因的年轻患者,分析甲氧苄啶-磺胺甲噁唑(TMP-SMX)相关严重急性呼吸衰竭的临床特征、病理与人类白细胞抗原(HLA)关联。患者均需ICU、机械通气,并频繁使用体外膜肺氧合。作者提出三部分诊断与评估策略:临床定义(治疗剂量TMP-SMX≥6天出现不明原因严重呼吸衰竭,为排除性诊断)、遗传关联(可获取基因组数据的11例全部携带HLA-B*07:02与HLA-C*07:02等位基因)、肺部病理(弥漫性肺泡损伤伴上皮化延迟)。作者认为需向临床医生传达这一相对罕见但危及生命的疾病,死亡率接近40%。

要点

  • 临床定义:接受治疗剂量(非预防剂量)TMP-SMX≥6天者出现不明原因严重呼吸衰竭,且TMP-SMX相关ARDS为排除性诊断。
  • 可获取基因组数据的11例TMP-SMX呼吸衰竭患者100%携带HLA-B*07:02与HLA-C*07:02等位基因。
  • 肺部病理可见独特模式:弥漫性肺泡损伤伴上皮化延迟。
  • 19例年轻患者(10-37岁)均既往健康、无肺部疾病及其他呼吸衰竭病因、无慢性吸烟/电子烟史,均需ICU与机械通气,并频繁使用体外膜肺氧合。
  • 作者报告该病死亡率接近40%,认为必须向临床医生传达这一相对罕见但危及生命的疾病。

适用人群与场景

  • 19例10-37岁年轻患者,既往健康,无既存肺部疾病、无其他呼吸衰竭病因、无慢性吸烟/电子烟史。
  • 场景为美国ICU,1996-2021年。

诊断标准与关键阈值

  • 临床定义:接受治疗剂量(非预防剂量)TMP-SMX≥6天者出现不明原因严重呼吸衰竭;TMP-SMX相关ARDS为排除性诊断。
  • 遗传关联:可获取基因组数据的11例患者100%携带HLA-B*07:02与HLA-C*07:02等位基因。
  • 肺部病理:弥漫性肺泡损伤伴上皮化延迟。

处置流程与药物剂量

  • 对疑似TMP-SMX呼吸衰竭患者,可考虑进行HLA等位基因评估。
  • 对疑似病例,可考虑在临床病程早期行外科肺活检。

红旗征与不能漏的情况

  • 接受治疗剂量TMP-SMX≥6天者出现不明原因严重呼吸衰竭,需ICU admission、机械通气,并频繁使用体外膜肺氧合。
  • 该病死亡率接近40%。

研究设计与关键结果

  • 回顾性研究纳入19例10-37岁既往健康患者,均无既存肺部疾病、无其他呼吸衰竭病因、无慢性吸烟/电子烟史;均需ICU admission、机械通气,并频繁使用体外膜肺氧合。
  • 可获取基因组数据的11例患者100%携带HLA-B*07:02与HLA-C*07:02等位基因。
  • 肺部病理可见弥漫性肺泡损伤伴上皮化延迟。
  • 死亡率接近40%。

证据类型、等级与局限

  • 证据类型:回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,应将这一相对罕见但危及生命的TMP-SMX相关严重急性呼吸衰竭告知临床医生。
  • 作者提出对疑似TMP-SMX呼吸衰竭患者可考虑HLA等位基因评估,对疑似病例可考虑早期外科肺活检。
  • 临床定义可用于识别接受治疗剂量TMP-SMX≥6天出现不明原因严重呼吸衰竭的患者,该诊断为排除性诊断。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Trimethoprim-sulfamethoxazole (TMP-SMX)-associated severe acute respiratory distress syndrome (ARDS) has gone underrecognized. We propose the first disease definition and clinical evaluation for a novel adverse drug reaction (ADR) based on a series of recently identified rare cases of life-threatening ADRs.

DESIGN: A retrospective study was conducted. All medical records were evaluated. Available pathology samples were sent to Massachusetts General for clinical consultation. Blood samples from surviving patients were obtained and human leukocyte antigen (HLA) analysis was performed by the Children's Mercy Hospital Genomic Center and Vanderbilt University Medical Center.

SETTING: U.S. ICUs, 1996-2021.

PATIENTS: Nineteen young patients (10-37) were identified. Patients were previously healthy, with no preexisting pulmonary disease, no other cause for respiratory failure, and no chronic history of smoking/vaping.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Through our retrospective analysis, we analyzed clinical characteristics associated with TMP-SMX. Pathology samples were reviewed, and HLA analysis was performed on available samples by the study team or as standard of care at treatment hospitals in some cases. In 19 critically ill patients, we identified a pattern of severe respiratory failure requiring ICU admission, mechanical ventilation, and frequent extracorporeal membrane oxygenation use. We describe the first three-part clinical diagnosis and evaluation strategy: 1) Clinical definition: Unexplained severe respiratory failure in a patient receiving greater than or equal to 6 days of TMP-SMX at treatment dose (not prophylaxis). TMP-SMX ARDS is a diagnosis of exclusion. 2) Genetic association: One hundred percent of currently available TMP-SMX respiratory failure patient genomic data, ( n = 11) have been carriers of both HLA-B*07:02 and HLA-C*07:02 alleles. HLA allele evaluation could be considered in patients with suspected TMP-SMX respiratory failure. 3) Lung pathology: A unique pulmonary pathologic pattern of lung injury termed diffuse alveolar injury with delayed epithelialization has been observed in these cases. In suspected cases, surgical lung biopsy early in the clinical course could be considered.

CONCLUSIONS: TMP-SMX is a commonly prescribed antibiotic. However, we find it imperative to share this relatively rare but life-threatening condition with clinicians as the mortality rate approaches 40%.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Miller J, Khan H, Mino-Kenudson M, et al. Definition and Clinical Evaluation for Trimethoprim-Sulfamethoxazole Severe Acute Respiratory Failure. Crit Care Med. 2023. PMID: 37449964. doi:10.1097/CCM.0000000000006002

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。